Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Direct microglia replacement reveals pathologic and therapeutic contributions of brain macrophages to a monogenic neurological disease

ABSTRACT: Direct microglia replacement reveals pathologic and therapeutic contributions of brain macrophages to a monogenic neurological disease

PROVIDER: PRJNA1215700 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR32125200.fastq.gz	Fastqsanger.gz
	SRR32125201.fastq.gz	Fastqsanger.gz
	SRR32125202.fastq.gz	Fastqsanger.gz
	SRR32125203.fastq.gz	Fastqsanger.gz
	SRR32125204.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Direct microglia replacement reveals pathologic and therapeutic contributions of brain macrophages to a monogenic neurological disease [RNA-seq]

Project description:Direct microglia replacement reveals pathologic and therapeutic contributions of brain macrophages to a monogenic neurological disease [RNA-seq]

| PRJNA1217888 | ENA

Direct microglia replacement reveals pathologic and therapeutic contributions of brain macrophages to a monogenic neurological disease

Project description:Krabbe disease, also named Globoid Cell Leukodystrophy (GLD) for its distinct lipid- laden macrophages, is a severe leukodystrophy caused by galactosylceramidase (GALC) mutations. Hematopoietic stem cell transplant (HSCT) ameliorates disease and is associated with central nervous system (CNS) engraftment of GALC+ donor macrophages. Yet, the role of macrophages in GLD pathophysiology and HSCT remains unclear. Using single-cell sequencing we revealed early interferon response signatures which precede progressively severe macrophage dyshomeostasis, and identified a molecular signature of globoid cells, which we validated in human brain specimens. Genetic depletion and direct microglia replacement by CNS monocyte injection rapidly replaced >80% of endogenous microglia with healthy monocytes in the twitcher (GalcW355*) mouse, a faithful model of GLD. Perinatal microglia replacement completely normalized transcriptional signatures, rescued histopathology, and doubled average survival. Overall, we uncovered distinct forms of microglia dysfunction, and evidence that direct, CNS-limited microglia replacement improves a monogenic neurodegenerative disease, a promising therapeutic target.

2025-04-30 | GSE288018 | GEO

Direct microglia replacement reveals pathologic and therapeutic contributions of brain macrophages to a monogenic neurological disease [RNA-seq]

2025-04-30 | GSE288504 | GEO

Monogenic diabetes study

Project description:Monogenic diabetes

| PRJEB48347 | ENA

Skin Microbiome of Monogenic Skin Disorder

Project description:Skin Microbiome of Monogenic Skin Disorder

| PRJNA1168594 | ENA

Skin Microbiome of Monogenic Skin Disorder

Project description:Skin Microbiome of Monogenic Skin Disorder

| PRJNA1168593 | ENA

Sporulation: TAO3 replacement strains

Project description:Sporulation: TAO3 replacement strains

| PRJEB8698 | ENA

Dog neurological disease

Project description:Dog neurological disease-identification of mutation

| PRJEB71373 | ENA

Cigarette smoking induces changes in airway epithelial expression of genes associated with monogenic lung disorders

Project description:Smoking-induced lung disease is one of the most prevalent forms of lung disease but also one of the more diverse. Based on the phenotypic diversity caused by the same environmental stress, we hypothesized that smoking may induce changes in lung cell expression of genes that, with specific variants, are causative of monogenic lung disease, i.e., not that smoking induces a phenocopy of a genetic disease, but smoking may subtly modify the expression of genes known to be associated with genetic disorders with distinct lung disease phenotypes. To assess this hypothesis, and based on the knowledge that most smoking-related disease phenotypes start in the small airway epithelium, we asked: are the genes associated with the monogenic lung disorders expressed in the small airway epithelium, and if so, does smoking alter the expression of these genes? To accomplish this, we examined small airway epithelium expression of 92 genes known to be associated with 17 monogenic lung disorders in 230 samples of small airway epithelium (SAE) obtained from healthy nonsmokers and healthy smokers without any clinical evidence of disease. Of the 86 monogenic disorder-related genes we found expressed in the SAE, strikingly, 37 were significantly differentially expressed in normal smokers compared to normal nonsmokers (p<0.05, Benjamini-Hochberg correction for multiple comparisons). The data demonstrates that the effect of smoking on the transcriptome of small airway epithelium includes significantly altered regulation of the genes responsible for known monogenic disorders.

2017-08-30 | GSE63127 | GEO

Amelioration of Pathologic -Synuclein-Induced Parkinson’s Disease by Irisin

Project description:Physical activity is thought to provide clinical benefit in Parkinson’s diseas (PD). Irisin is a blood-brain barrier permeable exercise-induced polypeptide secreted by muscle that mediates, in part, the beneficial effects of exercise. Here we show that irisin prevents pathologic -synuclein (-syn) induced neurodegeneration in the -syn preformed fibril mouse model of sporadic PD. Intravenous delivery of adenoviral irisin in vivo after the stereotaxic intrastriatal injection of -syn pre-formed fibrils reduced the formation of pathologic -syn and prevented the loss of dopamine neurons and reductions in striatal dopamine. Irisin also reduced the -syn pre-formed fibril induced motor deficits as assessed by the pole test and grip strength test. Administration of recombinant irisin in primary cortical neurons prevented pathologic -syn toxicity. Tandem mass spectrometry and biochemical analysis revealed that irisin reduced pathologic -syn by enhancing endolysosomal degradation of pathologic -syn. Our findings highlight the potential for therapeutic disease modification of irisin in PD.

2022-10-15 | PXD032670 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data